Solid Biosciences’ (SLDB) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Solid Biosciences (NASDAQ:SLDB) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $15.00 target price on the stock.

A number of other research analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Wednesday, October 8th. Wall Street Zen downgraded Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Wedbush decreased their price target on Solid Biosciences from $17.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, August 13th. Barclays set a $9.00 price objective on Solid Biosciences and gave the company an “overweight” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. decreased their target price on Solid Biosciences from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.70.

Solid Biosciences Trading Up 7.4%

SLDB opened at $4.22 on Tuesday. The stock has a 50-day moving average of $5.59 and a 200 day moving average of $5.04. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $7.37. The firm has a market cap of $328.78 million, a P/E ratio of -1.69 and a beta of 2.75.

Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Monday, November 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, research analysts forecast that Solid Biosciences will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its position in Solid Biosciences by 80.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,308 shares of the company’s stock valued at $57,000 after purchasing an additional 6,836 shares during the period. CWM LLC lifted its holdings in Solid Biosciences by 15,188.5% during the first quarter. CWM LLC now owns 7,950 shares of the company’s stock worth $29,000 after buying an additional 7,898 shares during the period. Allianz Asset Management GmbH bought a new stake in Solid Biosciences during the 1st quarter valued at $100,000. XTX Topco Ltd bought a new stake in Solid Biosciences during the first quarter valued at about $151,000. Finally, Sfmg LLC bought a new stake in shares of Solid Biosciences in the 1st quarter valued at about $93,000. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.